Barclays (LON:BARC) analyst Luke Sergott maintained a Buy rating on Twist Bioscience (NASDAQ:TWST) Corp on Friday, setting a price target of $130, which is approximately 60.22% above the present share price of $81.14.
Sergott expects Twist Bioscience Corp to post earnings per share (EPS) of -$0.84 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Twist Bioscience, with an average price target of $117.67.
The analysts price targets range from a high of $130 to a low of $110.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $37.95 million and a net profit of -$42.23 million. The company's market cap is $4.03 billion.
According to TipRanks.com, Barclays analyst Luke Sergott is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 23.9% and a 58.54% success rate.
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.